Viewing nowBoo-Kwang Valsartan Tablet 80 mg
Valsartan 80mg
Tablet · Prescription medication
Boo-Kwang Pharmaceutical Co., Ltd.

MFDS item code 201207380 · Approved 2012.10.23 · Insurance code 642203130
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension. It also assists heart failure patients (NYHA class II to IV) who cannot use ACE inhibitors. For patients with reduced left ventricular function after myocardial infarction, this drug contributes to lowering the risk of death, thus effectively improving heart function and providing preventive treatment. Accordingly, this medication is used for hypertension, heart failure, and preventing complications after myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that this medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg orally once daily as valsartan, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg once daily of this medicine. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily of this medicine. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily of this medicine. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg once daily of this medicine; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily of this medicine, and the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily of this medicine; over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents younger than 18 years. Safety and efficacy have not been established in children and adolescents younger than 18 years.
This drug should not be taken by women who are pregnant or may become pregnant, as it can cause serious harm to the fetus. If pregnancy is confirmed, discontinue use immediately. Patients with allergies to this medication or severe impairment of liver and kidney function, as well as those with a history of certain angioedema, should avoid use. Additionally, patients with moderate to severe kidney impairment among diabetics should not use this drug in combination with certain other medications. Elderly patients or those with elevated potassium levels, and patients with mild liver impairment, should exercise extra caution when using this medication. Patients with heart valve abnormalities or cardiovascular diseases should also be careful to avoid excessively low blood pressure. This medication can cause a rapid decrease in blood pressure, so patients undergoing dialysis or taking diuretics may experience symptoms of hypotension when they start taking it. If hypotension symptoms occur, immediate medical attention is necessary. This drug can interact with other antihypertensives, diuretics, and potassium-sparing agents, so patients on other medications should inform their healthcare providers. In particular, concurrent use with drugs that can elevate potassium levels may increase the risk of hyperkalemia. While taking this medication, dizziness or drowsiness may occur; hence caution should be exercised while driving or operating machinery. If pregnant, taking this drug may lead to severe side effects such as impaired renal function in the fetus, craniosynostosis, and therefore it should not be taken during pregnancy. Breastfeeding women are also advised to avoid this medication. Safety and efficacy have not been established in children and adolescents, and its use is not recommended. In case of overdose, severe hypotension or reduced consciousness may occur, necessitating immediate hospital treatment. This drug should be kept out of the reach of children and should not be transferred to another container as it may adversely affect quality.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air and moisture. It is also important to keep it in a cool place at or below 30 degrees Celsius to maintain its effectiveness.
Pale pink round film-coated tablet
98 tablets (14 tablets/PTP x 7)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Boo-Kwang Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.